|
1
|
Adlercreutz H, Musey PI, Fotsis T, et al:
Identification of lignans and phytoestrogens in urine of
chimpanzees. Clin Chim Acta. 158:147–154. 1896. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
L’homme R, Brouwers E, Al-Maharik N, et
al: Time-resolved fluoroimmunoassay of plasma and urine
O-desmethylangolensin. J Steroid Biochem Mol Biol. 81:353–361.
2002.PubMed/NCBI
|
|
3
|
Arai Y, Uehara M, Sato Y, et al:
Comparison of isoflavones among dietary intake, plasma
concentration and urinary excretion for accurate estimation of
phytoestrogen intake. J Epidemiol. 10:127–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frankenfeld CL, McTiernan A, Aiello EJ, et
al: Mammographic density in relation to daidzein-metabolizing
phenotypes in overweight, postmenopausal women. Cancer Epidemiol
Biomarkers Prev. 13:1156–1162. 2004.PubMed/NCBI
|
|
5
|
Kelly GE, Joannou GE, Reeder AY, et al:
The variable metabolic response to dietary isoflavones in humans.
Proc Soc Exp Biol Med. 208:40–43. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Setchell KD, Brown NM and Lydeking-Olsen
E: The clinical importance of the metabolite equol - a clue to the
effectiveness of soy and its isoflavones. J Nutr. 132:3577–3584.
2002.PubMed/NCBI
|
|
7
|
Bushinsky DA, Sessler NE and Krieger NS:
Greater unidirectional calcium efflux from bone during metabolic,
compared with respiratory, acidosis. Am J Physiol. 262:F425–F431.
1992.PubMed/NCBI
|
|
8
|
Jackman KA, Woodman OL and Sobey CG:
Isoflavones, equol and cardiovascular disease: pharmacological and
therapeutic insights. Curr Med Chem. 14:2824–2830. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagata C: Factors to consider in the
association between soy isoflavone intake and breast cancer risk. J
Epidemiol. 20:83–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Messina M, Nagata C and Wu AH: Estimated
Asian adult soy protein and isoflavone intakes. Nutr Cancer.
55:1–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin S, Zhang QY, Kang XM, et al: Daidzein
induces MCF-7 breast cancer cell apoptosis via the mitochondrial
pathway. Ann Oncol. 21:263–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang WH, Liu JJ, Chen CH, et al: Growth
inhibition and induction of apoptosis in MCF-7 breast cancer cells
by fermented soy milk. Nutr Cancer. 43:214–226. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Constantinou AI, Kamath N and Murley JS:
Genistein inactivates bcl-2, delays the G2/M phase of the cell
cycle, and induces apoptosis of human breast adenocarcinoma MCF-7
cells. Eur J Cancer. 34:1927–1934. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi EJ and Kim GH: Daidzein causes cell
cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7
and MDA-MB-453 cells. Phytomedicine. 15:683–690. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balabhadrapathruni S, Thomas TJ, Yurkow
EJ, et al: Effects of genistein and structurally related
phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468
human breast cancer cells. Oncol Rep. 7:3–12. 2000.PubMed/NCBI
|
|
16
|
Guo JM, Xiao BX, Liu DH, et al: Biphasic
effect of daidzein on cell growth of human colon cancer cells. Food
Chem Toxicol. 42:1641–1646. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang BY and Adams NR: Effect of equol on
oestrogen receptors and on synthesis of DNA and protein in the
immature rat uterus. J Endocrinol. 85:291–297. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shutt DA and Cox RI: Steroid and
phyto-oestrogen binding to sheep uterine receptors in vitro. J
Endocrinol. 52:299–310. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pfitscher A, Reiter E and Jungbauer A:
Receptor binding and transactivation activities of red clover
isoflavones and their metabolites. J Steroid Biochem Mol Biol.
112:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Casagrande F and Darbon JM: Effects of
structurally related flavonoids on cell cycle progression of human
melanoma cells: regulation of cyclin-dependent kinases CDK2 and
CDK1. Biochem Pharmacol. 61:1205–1215. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Woo HH, Jeong BR and Hawes MC: Flavonoids:
from cell cycle regulation to biotechnology. Biotechnol Lett.
27:365–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singh RP and Agarwal R: Natural flavonoids
targeting deregulated cell cycle progression in cancer cells. Curr
Drug Targets. 7:345–354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
24
|
Collins I and Garrett MD: Targeting the
cell division cycle in cancer: CDK and cell cycle checkpoint kinase
inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Li M, Rayburn ER, et al:
Oncogenes as novel targets for cancer therapy (part IV): regulators
of the cell cycle and apoptosis. Am J Pharmacogenomics. 5:397–407.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee B, Kim CH and Moon SK: Honokiol causes
the p21WAF1-mediated G(1)-phase arrest of the cell cycle through
inducing p38 mitogen activated protein kinase in vascular smooth
muscle cells. FEBS Lett. 580:5177–5184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng C, Zhang P, Harper JW, et al: Mice
lacking p21CIP1/WAF1 undergo normal development, but are defective
in G1 checkpoint control. Cell. 82:675–684. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takizawa CG and Morgan DO: Control of
mitosis by changes in the subcellular location of cyclin-B1-Cdk1
and Cdc25C. Curr Opin Cell Biol. 12:658–665. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Porter LA and Donoghue DJ: Cyclin B1 and
CDK1: nuclear localization and upstream regulators. Prog Cell Cycle
Res. 5:335–347. 2003.PubMed/NCBI
|
